P A Pavco

Phio Pharmaceuticals (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index1.6kcitations39works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA and protein synthesis mechanisms(9), RNA Interference and Gene Delivery(9), Monoclonal and Polyclonal Antibodies Research(7), MicroRNA in disease regulation(5), Hepatitis C virus research(5)

Publications39 total

A Phase 1/2 multidose, dose escalation study to evaluate RXI-109 administered by intravitreal injection to reduce the progression of subretinal fibrosis in subjects with advanced neovascular AMD (NVAMD)
2017
sd-rxRNA®: Self-Delivering RNAi Compounds Show Potential for Corneal Indications Following Topical Application
Investigative Ophthalmology & Visual Science·2016Open Access
Diphencyprone Treatment of Alopecia Areata: Postulated Mechanism of Action and Prospects for Therapeutic Synergy with RNA Interference
Journal of Investigative Dermatology Symposium Proceedings·2015· 9 citedOpen Access
MDM2 Targeting sd-rxRNA® for Retinoblastoma Therapy
Investigative Ophthalmology & Visual Science·2015
Formulation and Release of sd-rxRNA® from a Cross-linked, Thiolated CMHA-based Film for Topical Delivery to Reduce the Formation of Corneal Scarring
Investigative Ophthalmology & Visual Science·2015
RXI-109 Treatment for Proliferative Vitreoretinopathy (PVR) and other Ocular Disorders
2014· 4 cited
An Update on the Development of sd-rxRNA for Retinoblastoma Therapy
2014
Novel Hydrophobically Modified Asymmetric RNAi Compounds (sd-rxRNA) Demonstrate Robust Efficacy in the Eye
Journal of Ocular Pharmacology and Therapeutics·2013· 77 cited
Development of sd-rxRNA® for Retinoblastoma Therapy
2013
Oligo Safety Working Group Exaggerated Pharmacology Subcommittee Consensus Document
Nucleic Acid Therapeutics·2013· 45 cited
Novel Anti-CTGF RNAi Therapy for Treatment of Proliferative Vitreoretinopathy (PVR) and other Ocular Disorders
2012· 1 cited
Self-delivering RNAi Compounds (sd-rxRNATm) Demonstrate Robust Efficacy In Vivo In The Mouse Eye
Investigative Ophthalmology & Visual Science·2011
Novel Self-Delivering RNAi Compounds (sd-rxRNATM) Demonstrate Robust Ocular Cell Uptake in vitro and in vivo
2010
Modified dsRNAs that are not processed by Dicer maintain potency and are incorporated into the RISC
Nucleic Acids Research·2010· 32 citedOpen Access
Delivery to Macrophages and Efficacy of Orally Administered RNAi Compounds (42.27)
The Journal of Immunology·2009
Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1
Gene Therapy·2005· 305 cited
Identification of Stabilized Small Interfering RNAs (siRNAs) for the Potential Treatment of Age–related Macular Degeneration (AMD)
Investigative Ophthalmology & Visual Science·2005
Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) Plays an Important Role in the Development of Ocular Neovascularization (NV)
Investigative Ophthalmology & Visual Science·2004
Stabilized small interfering RNAs (siRNAs) targeting the vascular endothelial growth factor (VEGF) pathway inhibit angiogenesis in vivo in a rat corneal model
Investigative Ophthalmology & Visual Science·2004
Nuclease resistant ribozymes directed against hepatitis C virus RNA plus and minus strand inhibit viral replication of a HCV/poliovirus chimera
Elsevier eBooks·2003
page 1 of 2Next →

Frequent Co-authors

Karen Bulock(13), James Cardia(12), Michael Byrne(11), Karyn Bouhana(8), Lyn Libertine(8), Lawrence M. Blatt(6), Katherine Holton(6), Lakshmipathi Pandarinathan(5), Francine E. Wincott(4), Dennis G. Macejak(4), Anastasia Khvorova(4), Glenn C. Van Tuyle(4), Jennifer A. Sandberg(4), Kathy Fosnaugh(3), Chandra Vargeese(3), R. Aitchison(3), Peter A. Campochiaro(3), Adalberto M. Gallegos(3), Karin S. Blanchard(3), T J Parry(3)